Alerts will be sent to your verified email
Verify Email
GLAND
|
Gland Pharma
|
Caplin Point Lab
|
Gufic Biosciences
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
12.02 % | 20.61 % | 25.05 % |
|
5yr Avg Net Profit Margin
|
20.79 % | 24.8 % | 10.9 % |
|
Price to Book
|
3.36 | 9.42 | 6.06 |
|
P/E
|
39.97 | 45.43 | 58.83 |
|
5yr Avg Cash Conversion Cycle
|
69.81 Days | 79.85 Days | 26.94 Days |
|
5yr Average Interest Coverage Ratio
|
183.05 | 579.71 | 13.1 |
|
5yr Avg ROCE
|
16.55 % | 25.27 % | 27.25 % |
|
5yr Avg Operating Profit Margin
|
29.26 % | 30.87 % | 18.45 % |
|
5 yr average Debt to Equity
|
0.01 | 0.01 | 0.51 |
|
5yr CAGR Net Profit
|
-6.87 % | 16.28 % | 14.26 % |
|
5yr Average Return on Assets
|
10.65 % | 17.7 % | 11.52 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.83 % | 70.56 % | 72.52 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-6.04 % | 1.68 % | -2.48 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
15.13 % | 0.87 % | 2.35 % |
|
Gland Pharma
|
Caplin Point Lab
|
Gufic Biosciences
|
|---|